CSIMarket
 
Exact Sciences Corporation  (EXAS)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $57.7100 $-0.82 -1.401%
Day's High: $59.495 Week Perf: -4.93 %
Day's Low: $ 57.48 30 Day Perf: -7.05 %
Volume (M): 1,855 52 Wk High: $ 100.77
Volume (M$): $ 107,041 52 Wk Avg: $73.03
Open: $58.13 52 Wk Low: $56.05



 Market Capitalization (Millions $) 10,426
 Shares Outstanding (Millions) 181
 Employees 5,361
 Revenues (TTM) (Millions $) 2,532
 Net Income (TTM) (Millions $) -204
 Cash Flow (TTM) (Millions $) 367
 Capital Exp. (TTM) (Millions $) 124

Exact Sciences Corporation
Exact Sciences Corporation is a medical technology company headquartered in Madison, Wisconsin, that is focused on developing and commercializing diagnostic tests for the early detection and prevention of cancer. Founded in 1995, the company has risen to prominence as a leader in the field of molecular diagnostics, a branch of medicine that uses DNA and RNA analysis to identify and diagnose diseases.

The company's flagship product is Cologuard, a non-invasive, at-home fecal immunochemical test (FIT) for colorectal cancer screening. Cologuard uses advanced DNA and protein analysis to detect signs of colorectal cancer and precancerous growths, offering patients a comfortable and convenient alternative to traditional colonoscopies. Since its launch in 2014, Cologuard has become one of the most widely used and highly rated colorectal cancer screening tests in the United States.

In addition to Cologuard, Exact Sciences also offers a suite of other diagnostic products for cancer detection, including Oncotype DX, a genomic test for breast, colon, and prostate cancer; and ThyraMIR, a thyroid cancer test that uses microRNA analysis to detect malignant nodules.

The company has a strong commitment to research and development, with a dedicated team of scientists working to develop new diagnostic tests and improve existing products. In addition to its proprietary diagnostic platforms, Exact Sciences has also formed strategic partnerships with other leading medical technology companies to expand its capabilities in areas such as liquid biopsy and precision medicine.

As of 2021, Exact Sciences has grown to become a multi-billion-dollar company with more than 6,000 employees worldwide. The company has received numerous awards and accolades for its innovative products and commitment to improving healthcare outcomes, and is widely regarded as a leader in the field of molecular diagnostics.


   Company Address: 5505 Endeavor Lane Madison 53719 WI
   Company Phone Number: 284?5700   Stock Exchange / Ticker: NASDAQ EXAS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Advancements in Colon Cancer Screening: Cologuard Plus Test Proves to be a Game Changer

Published Wed, Mar 13 2024 9:03 PM UTC

In a significant stride towards revolutionizing cancer screening and diagnostics, Exact Sciences Corp. has announced the publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study titled Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening presents groundbreaking findings that highlight the efficacy of the Co...

Exact Sciences Corporation

Exact Sciences Corporation Surpasses Revenue Expectations, Yet Profitability Remains Elusive



The Medical Laboratories company, Exact Sciences Corporation, has reported impressive financial results in its most recent fiscal period. With a surge in revenue of 22.81% to $672.22 million from the same quarter a year prior, combined with a significant reduction in net loss per share, the company seems to be on a positive trajectory. Additionally, a rise in accounts receivable and reduced inventories signal a potential increase in demand. This article aims to interpret these financial results, highlighting the possible impacts on Exact Sciences Corporation going forward.
1. Improved Revenue:
Exact Sciences Corporation's revenue experienced substantial growth during the last fiscal year, reaching $672.22 million. This surge of 22.81% is a promising indicator of the company's ability to attract customers and expand its market share. The increase suggests that the company's offerings and services have received positive responses from both existing and new clients, resulting in higher sales.

Exact Sciences Corporation

Exact Sciences Corporation Surges to New Heights: Breakthrough Revenue Growth in Q3 2023

A Surge in Revenue Fails to Boost Income: Analyzing Exact Sciences Corporation's Q3 2023 Financial Report
As the third quarter of 2023 came to an end, Exact Sciences Corporation released their financial report, revealing that despite a remarkable surge in revenue, the company's income remained stagnant. The earnings per share stood at break-even at $0.00, which must have disappointed investors hoping for a more substantial growth in profitability.
However, it is important to note that the revenue for Exact Sciences Corporation took a significant leap of 22.53% compared to the same period last year, reaching an impressive $630.40 million. This rise in revenue puts Exact Sciences Corporation ahead of many of its counterparts in the Medical Laboratories sector, as the majority of corporations in this sector reported a mere 0.36% increase in business over the same period.

Exact Sciences Corporation

Exact Sciences Corporation Witnesses a Remarkable 21.046% Revenue Surge to $626.92 Million in Q2 2023

The financial results for Exact Sciences Corporation (EXAS) in the second quarter of 2023 indicate both positive and negative aspects for the company. On one hand, there was a significant surge in revenue, with a growth rate of 21.046% compared to the same period in the previous year. This resulted in a total revenue of $626.92 million, showcasing a strong performance in sales.
However, the company reported a loss of $-0.45 per share, representing a sequential increase in the deficit from the previous quarter's $-0.42 per share. Despite the boost in revenue, EXAS was unable to turn a profit in this particular quarter. This loss per share might be a concern for investors, especially considering the increase from the previous quarter.






 

Exact Sciences's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Exact Sciences does not provide revenue guidance.

Earnings Outlook
Exact Sciences Corporation does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com